Novo Nordisk acquires Dicerna for USD 3.3bn

Novo Nordisk is acquiring the US-based biotech business Dicerna for USD 3.3bn. The two companies are already collaborating within NASH, type 2 diabetes and obesity, in addition to rare diseases.

Photo: Tidsvilde Stine/Ritzau Scanpix

On Thursday, Novo Nordisk announces in a press release that it is acquiring the US-based firm Dicerna, which has been a frequent collaborator of the Danish pharmaceutical company since 2019.

According to Novo Nordisk, the price tag reads around USD 3.3bn.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs